AGC Biologics Partners with Child’s Cure Genetic Research to Pursue mRNA-Based Therapeutic for Severe Epileptic Disorder

Share:

AGC Biologics will apply its mRNA service line, launched in 2023 at its Heidelberg site, to early proof-of-concept work identifying a development path toward the clinic. Drawing on 40 years of fermentation experience, the service spans R&D to GMP-grade supply. A Yokohama, Japan, location will add mRNA capabilities in 2027.

Share: